PA
SEEL

Procyon Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Procyon Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed -$5K – 1112
2020
Q2 		$5K Hold
1
– – ﹤0.01% 807
2020
Q1 		$1K Hold
1
– – ﹤0.01% 972
2019
Q4 		$3K Buy
+1
New +$3.83K ﹤0.01% 880

Other funds holding SEEL

UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Procyon Advisors's SEEL Position: Q3 2020 in Review

Procyon Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2020, closing a stake of 1 share — an estimated $5K sold.

Procyon Advisors first reported a position in SEEL in Q4 2019 and held it in 3 quarters. The position peaked at $5K in Q2 2020. 24 funds tracked by Wall St. Rank hold SEEL as of Q3 2020.

  • Procyon Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Procyon Advisors sold 1 Seelos Therapeutics, Inc. Common Stock share in Q3 2020, an estimated $5K.
  • Procyon Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Procyon Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $5K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.